X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs ALKEM LABORATORIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES ALKEM LABORATORIES JUBILANT LIFE SCIENCES/
ALKEM LABORATORIES
 
P/E (TTM) x 15.7 - - View Chart
P/BV x 4.6 6.7 69.3% View Chart
Dividend Yield % 0.4 0.7 60.6%  

Financials

 JUBILANT LIFE SCIENCES   ALKEM LABORATORIES
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
ALKEM LABORATORIES
Mar-16
JUBILANT LIFE SCIENCES/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1871,589 11.8%   
Low Rs651,232 5.3%   
Sales per share (Unadj.) Rs364.3417.5 87.3%  
Earnings per share (Unadj.) Rs6.856.3 12.2%  
Cash flow per share (Unadj.) Rs24.564.7 37.9%  
Dividends per share (Unadj.) Rs3.0012.70 23.6%  
Dividend yield (eoy) %2.40.9 264.5%  
Book value per share (Unadj.) Rs164.9292.9 56.3%  
Shares outstanding (eoy) m159.28119.57 133.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.4 10.2%   
Avg P/E ratio x18.425.1 73.4%  
P/CF ratio (eoy) x5.121.8 23.6%  
Price / Book Value ratio x0.84.8 15.9%  
Dividend payout %43.822.6 194.3%   
Avg Mkt Cap Rs m20,061168,653 11.9%   
No. of employees `0006.2NA-   
Total wages/salary Rs m11,0529,171 120.5%   
Avg. sales/employee Rs Th9,383.0NM-  
Avg. wages/employee Rs Th1,786.9NM-  
Avg. net profit/employee Rs Th176.3NM-  
INCOME DATA
Net Sales Rs m58,03449,915 116.3%  
Other income Rs m1911,645 11.6%   
Total revenues Rs m58,22451,561 112.9%   
Gross profit Rs m5,7868,482 68.2%  
Depreciation Rs m2,8121,006 279.5%   
Interest Rs m3,237671 482.7%   
Profit before tax Rs m-728,451 -0.9%   
Minority Interest Rs m-286-114 251.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m6961,606 43.4%   
Profit after tax Rs m1,0906,731 16.2%  
Gross profit margin %10.017.0 58.7%  
Effective tax rate %-965.919.0 -5,082.6%   
Net profit margin %1.913.5 13.9%  
BALANCE SHEET DATA
Current assets Rs m29,28027,062 108.2%   
Current liabilities Rs m38,91215,324 253.9%   
Net working cap to sales %-16.623.5 -70.6%  
Current ratio x0.81.8 42.6%  
Inventory Days Days8467 126.9%  
Debtors Days Days5141 122.8%  
Net fixed assets Rs m55,71212,610 441.8%   
Share capital Rs m155239 64.6%   
"Free" reserves Rs m20,96834,490 60.8%   
Net worth Rs m26,26535,027 75.0%   
Long term debt Rs m17,1691,212 1,417.0%   
Total assets Rs m88,60654,387 162.9%  
Interest coverage x1.013.6 7.2%   
Debt to equity ratio x0.70 1,889.7%  
Sales to assets ratio x0.70.9 71.4%   
Return on assets %4.913.6 35.9%  
Return on equity %4.219.2 21.6%  
Return on capital %11.624.9 46.5%  
Exports to sales %37.812.9 292.0%   
Imports to sales %16.53.1 534.2%   
Exports (fob) Rs m21,9336,461 339.5%   
Imports (cif) Rs m9,5671,540 621.1%   
Fx inflow Rs m22,0046,563 335.3%   
Fx outflow Rs m11,7493,012 390.1%   
Net fx Rs m10,2553,552 288.7%   
CASH FLOW
From Operations Rs m8,0267,259 110.6%  
From Investments Rs m-1,7441,864 -93.6%  
From Financial Activity Rs m-4,447-9,273 48.0%  
Net Cashflow Rs m1,834-150 -1,223.0%  

Share Holding

Indian Promoters % 45.6 66.9 68.2%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 33.1 26.3%  
FIIs % 21.2 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 0.0 -  
Shareholders   23,815 68,381 34.8%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   ABBOTT INDIA  NATCO PHARMA  AJANTA PHARMA  PFIZER  DR. DATSONS LABS  

Compare JUBILANT LIFE SCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Strong; Realty & Automobile Stocks Lead(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.4% while the Hang Seng is up 0.1%.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY19); Net Profit Up 67.2% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 67.2% YoY). Sales on the other hand came in at Rs 23 bn (up 38.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY18); Net Profit Up 1.4% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 1.4% YoY). Sales on the other hand came in at Rs 23 bn (up 37.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Nov 19, 2018 12:15 PM

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 5-YR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS